Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial

European Journal of Cancer

Volumn 51, Issue 10, 2015, Pages 1274-1282

  Nishimura, Junichi ^a   Satoh, Taroh ^a   Fukunaga, Mutsumi ^b   Takemoto, Hiroyoshi ^b   Nakata, Ken ^b   Ide, Yoshihito ^c   Fukuzaki, Takayuki ^d   Kudo, Toshihiro ^a   Miyake, Yasuhiro ^e   Yasui, Masayoshi ^f   Morita, Shunji ^g   Sakai, Daisuke ^a   Uemura, Mamoru ^a   Hata, Taishi ^a   Takemasa, Ichiro ^a   Mizushima, Tsunekazu ^a   Ohno, Yuko ^a   Yamamoto, Hirofumi ^a   Sekimoto, Mitsugu ^h   Nezu, Riichiro ⁱ   Doki, Yuichiro ^a   Mori, Masaki ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Department of Clinical Research and Epidemiology   (Japan)

^c Yao Municipal Hospital   (Japan)

^d IKEDA MUNICIPAL HOSPITAL   (Japan)

^e Minoh City Hospital   (Japan)

^f Kaizuka City Hospital   (Japan)

^g TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^h OSAKA NATIONAL HOSPITAL   (Japan)

ⁱ Nishinomiya Municipal Hospital   (Japan)

Author keywords

Antiemetics; Aprepitant; Moderately emetogenic chemotherapy; Oxaliplatin

Indexed keywords

APREPITANT; AZASETRON; CAPECITABINE; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; FOSAPREPITANT; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANISETRON; INDISETRON; OXALIPLATIN; PALONOSETRON; RAMOSETRON; SEROTONIN 3 ANTAGONIST; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; MORPHOLINE DERIVATIVE; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CHEILITIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; FEVER; HAND FOOT SYNDROME; HICCUP; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; ILEUS; INCIDENCE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SKIN MANIFESTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DRUG COMBINATION; MIDDLE AGED;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; ORGANOPLATINUM COMPOUNDS; VOMITING;

EID: 84930045312     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.03.024     Document Type: Article

References (24)

1. T.H. Oo, and P.J. Hesketh Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting Nat Clin Pract Oncol 2 4 2005 196 201
2. J. Cassidy, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, and R. Wong Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 12 2008 2006 2012
3. A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, and J. Cassidy Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 16 2000 2938 2947
4. R.M. Goldberg, D.J. Sargent, R.F. Morton, C.S. Fuchs, R.K. Ramanathan, and S.K. Williamson A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 1 2004 23 30
5. H.J. Schmoll, T. Cartwright, J. Tabernero, M.P. Nowacki, A. Figer, and J. Maroun Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients J Clin Oncol 25 1 2007 102 109
6. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Antiemesis; 2014. Available from < http://www.nccn.org/professionals/physician-gls/pdf/antiemesis.pdf > [cited 28.09.14].
7. F. Roila, J. Herrstedt, M. Aapro, R.J. Gralla, L.H. Einhorn, and E. Ballatori Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann Oncol 21 suppl. 5 2010 v232 v243
8. E. Basch, A.A. Prestrud, P.J. Hesketh, M.G. Kris, P.C. Feyer, and M.R. Somerfield Antiemetics: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 29 31 2011 4189 4198
9. Japan Society of Clinical Oncology, Guideline: appropriate use of antiemetics. Tokyo: Kanehara & Co., Ltd; 2010 [in Japanese].
10. T. Andre, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, and T. Hickish Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 23 2004 2343 2351
11. M.L. Rothenberg, J.V. Cox, C. Butts, M. Navarro, Y.J. Bang, and R. Goel Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study Ann Oncol 19 10 2008 1720 1726
12. Y. Jin, X. Wu, Y. Guan, D. Gu, Y. Shen, and Z. Xu Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis Support Care Cancer 20 8 2012 1815 1822
13. P.J. Hesketh, S.M. Grunberg, R.J. Gralla, D.G. Warr, F. Roila, and R. de Wit The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group J Clin Oncol 21 22 2003 4112 4119
14. S. Poli-Bigelli, J. Rodrigues-Pereira, A.D. Carides, G. Julie Ma, K. Eldridge, and A. Hipple Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 97 12 2003 3090 3098
15. T. Takahashi, E. Hoshi, M. Takagi, N. Katsumata, M. Kawahara, and K. Eguchi Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin Cancer Sci 101 11 2010 2455 2461
16. B.L. Rapoport, K. Jordan, J.A. Boice, A. Taylor, C. Brown, and J.S. Hardwick Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study Support Care Cancer 18 4 2010 423 431
17. M. Tanioka, A. Kitao, K. Matsumoto, N. Shibata, S. Yamaguchi, and K. Fujiwara A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy Br J Cancer 109 4 2013 859 865
18. D.G. Warr, P.J. Hesketh, R.J. Gralla, H.B. Muss, J. Herrstedt, and P.D. Eisenberg Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 12 2005 2822 2830
19. S.M. Grunberg, J. Rolski, J. Strausz, Z. Aziz, S. Lane, and M.W. Russo Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial Lancet Oncol 10 6 2009 549 558
20. J. Herrstedt, W. Apornwirat, A. Shaharyar, Z. Aziz, F. Roila, and S. Van Belle Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy J Clin Oncol 27 32 2009 5363 5369
21. P.J. Hesketh, O. Wright, G. Rosati, M. Russo, J. Levin, and S. Lane Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study Support Care Cancer 20 7 2012 1471 1478
22. K. Sugihara, A. Ohtsu, Y. Shimada, N. Mizunuma, P.H. Lee, and A. de Gramont Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies Clin Colorectal Cancer 11 2 2012 127 137
23. C.E. Wu, and C.C. Liaw Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis Support Care Cancer 20 10 2012 2357 2361
24. P.J. Hesketh, J. Younger, P. Sanz-Altamira, M. Hayden, J. Bushey, and B. Trainor Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide Support Care Cancer 17 8 2009 1065 1070